Quest Diagnostics (DGX) Stock Price

Quest Diagnostics Price

NYSE·CLOSED
238.50USD+2.52 (+1.06 %)
Market closed

Over the last 19 years Quest Diagnostics grew revenue by 3.0% annually, reaching 11.04 B USD. Earnings per share have grown at 5.8% per year over the last 19 years. For Quest Diagnostics, the net margin of 9.0% is down versus 18.5% a few years ago. At today's price the dividend yield works out to roughly 1.32%. The payout ratio is around 36% of earnings. The dividend has grown at 11.6% per year over the past 19 years. The consensus 12-month price target for Quest Diagnostics is 207.06 USD, about 13.2% below where the stock trades today. Of 24 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 37% above its 52-week low.

Quest Diagnostics stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Quest Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Quest Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Quest Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Quest Diagnostics Stock Price History
DateQuest Diagnostics Price
8/6/2026238.50 USD
8/5/2026235.98 USD
8/4/2026232.80 USD
8/3/2026231.95 USD
7/31/2026233.01 USD
7/30/2026234.30 USD
7/29/2026235.80 USD
7/27/2026229.82 USD
7/23/2026227.90 USD
7/22/2026209.83 USD
7/21/2026206.84 USD
7/20/2026207.66 USD
7/17/2026210.68 USD
7/16/2026209.41 USD
7/15/2026201.77 USD
7/14/2026206.00 USD
7/13/2026208.99 USD
7/10/2026207.44 USD
7/9/2026208.05 USD
7/8/2026209.04 USD
7/7/2026212.38 USD
7/6/2026214.52 USD
7/2/2026215.72 USD
7/1/2026216.02 USD
6/30/2026211.95 USD
6/29/2026209.41 USD
6/26/2026209.88 USD
6/25/2026206.24 USD
6/24/2026203.11 USD
6/23/2026197.18 USD
6/22/2026193.65 USD
6/18/2026193.75 USD
6/17/2026197.81 USD
6/16/2026202.79 USD
6/15/2026201.50 USD
6/12/2026204.98 USD
6/11/2026204.70 USD
6/10/2026205.70 USD
6/9/2026204.53 USD
6/8/2026197.21 USD
6/5/2026200.02 USD
6/4/2026198.38 USD
6/3/2026193.15 USD
6/2/2026191.97 USD
6/1/2026193.62 USD
5/29/2026196.44 USD
5/28/2026195.65 USD
5/27/2026194.59 USD
5/26/2026193.78 USD
5/22/2026195.14 USD
5/21/2026192.59 USD
5/20/2026193.21 USD
5/19/2026190.39 USD
5/18/2026189.84 USD
5/15/2026186.61 USD
5/14/2026187.94 USD
5/13/2026190.85 USD
5/12/2026190.18 USD
5/11/2026189.81 USD
5/8/2026187.39 USD
5/7/2026190.84 USD
5/6/2026189.13 USD
5/5/2026190.84 USD
5/4/2026191.50 USD
5/1/2026192.67 USD
4/30/2026194.20 USD
4/29/2026189.32 USD
4/28/2026195.05 USD
4/27/2026196.63 USD
4/24/2026196.27 USD
4/23/2026199.53 USD
4/22/2026204.00 USD
4/21/2026205.04 USD
4/20/2026196.31 USD
4/17/2026195.02 USD
4/16/2026191.46 USD
4/15/2026191.42 USD
4/14/2026194.16 USD
4/13/2026192.91 USD
4/10/2026191.51 USD
4/9/2026197.82 USD
4/8/2026198.81 USD
4/7/2026196.81 USD
4/6/2026198.96 USD
4/2/2026198.02 USD
4/1/2026197.69 USD
3/31/2026195.98 USD
3/30/2026197.16 USD
3/27/2026195.51 USD
3/26/2026198.15 USD
3/25/2026196.46 USD
3/24/2026196.08 USD
3/23/2026195.60 USD
3/20/2026195.26 USD
3/19/2026194.01 USD
3/18/2026194.16 USD
3/17/2026198.61 USD
3/16/2026198.94 USD
3/13/2026199.70 USD
3/12/2026200.88 USD
3/11/2026200.56 USD
3/10/2026200.90 USD
3/9/2026201.58 USD
3/6/2026199.21 USD
3/5/2026203.98 USD
3/4/2026208.45 USD
3/3/2026208.36 USD
3/2/2026210.25 USD
2/27/2026211.91 USD
2/26/2026211.10 USD
2/25/2026207.80 USD
2/24/2026209.54 USD
2/23/2026207.43 USD
2/20/2026202.41 USD
2/19/2026202.44 USD
2/18/2026204.39 USD
2/17/2026205.49 USD
2/13/2026206.87 USD
2/12/2026206.86 USD
2/11/2026209.32 USD
2/10/2026205.35 USD
2/9/2026191.25 USD
2/6/2026190.71 USD
2/5/2026192.30 USD
2/4/2026189.23 USD
2/3/2026185.17 USD
2/2/2026185.00 USD
1/30/2026187.03 USD
1/29/2026182.35 USD
1/28/2026182.74 USD
1/27/2026184.24 USD
1/26/2026182.53 USD
1/23/2026181.02 USD
1/22/2026182.16 USD
1/21/2026184.65 USD
1/20/2026188.95 USD
1/16/2026189.49 USD
1/15/2026190.26 USD
1/14/2026186.77 USD
1/13/2026179.96 USD
1/12/2026175.94 USD
1/9/2026174.45 USD
1/8/2026177.74 USD
1/7/2026178.14 USD
1/6/2026180.46 USD
1/5/2026173.49 USD
1/2/2026173.79 USD
12/31/2025173.53 USD
12/30/2025175.49 USD
12/29/2025175.52 USD
12/26/2025175.94 USD
12/24/2025175.92 USD
12/23/2025175.08 USD
12/22/2025176.34 USD
12/19/2025176.06 USD
12/18/2025176.15 USD
12/17/2025179.10 USD
12/16/2025178.66 USD
12/15/2025184.11 USD
12/12/2025182.56 USD
12/11/2025181.57 USD
12/10/2025179.51 USD
12/9/2025179.62 USD
12/8/2025181.82 USD
12/5/2025182.51 USD
12/4/2025184.18 USD
12/3/2025182.61 USD
12/2/2025182.55 USD
12/1/2025183.77 USD
11/28/2025189.18 USD
11/26/2025189.69 USD
11/25/2025192.35 USD
11/24/2025190.58 USD
11/21/2025191.25 USD
11/20/2025187.61 USD
11/19/2025185.96 USD
11/18/2025185.32 USD
11/17/2025186.19 USD
11/14/2025186.95 USD
11/13/2025187.58 USD
11/12/2025186.85 USD
11/11/2025188.85 USD
11/10/2025184.31 USD
11/7/2025179.50 USD
11/6/2025176.51 USD
11/5/2025178.26 USD
11/4/2025178.03 USD
11/3/2025178.84 USD
10/31/2025175.95 USD
10/30/2025175.76 USD
10/29/2025174.78 USD
10/28/2025178.28 USD
10/27/2025180.26 USD
10/24/2025182.38 USD
10/23/2025183.23 USD
10/22/2025181.17 USD
10/21/2025184.64 USD
10/20/2025190.41 USD
10/17/2025189.51 USD
10/16/2025186.82 USD
10/15/2025187.35 USD
10/14/2025185.39 USD
10/13/2025182.78 USD
10/10/2025184.08 USD
10/9/2025181.44 USD
10/8/2025180.89 USD
10/7/2025181.89 USD
10/6/2025178.43 USD
10/3/2025179.34 USD
10/2/2025180.96 USD
10/1/2025182.07 USD
9/30/2025190.58 USD
9/29/2025188.84 USD
9/28/2025188.84 USD
9/25/2025188.99 USD
9/24/2025185.39 USD
9/23/2025186.97 USD
9/22/2025184.69 USD
9/19/2025183.61 USD
9/18/2025183.33 USD
9/17/2025182.25 USD
9/16/2025180.16 USD
9/15/2025180.62 USD
9/12/2025183.72 USD
9/11/2025183.46 USD
9/10/2025180.14 USD
9/9/2025182.68 USD
9/8/2025182.53 USD
9/5/2025183.49 USD
9/4/2025180.11 USD
9/3/2025179.51 USD
9/2/2025178.70 USD
8/29/2025181.64 USD
8/28/2025179.20 USD
8/27/2025179.76 USD
8/26/2025180.36 USD
8/25/2025178.66 USD
8/22/2025180.24 USD
8/21/2025183.72 USD
8/20/2025184.40 USD
8/19/2025182.83 USD
8/18/2025178.95 USD
8/15/2025179.77 USD
8/14/2025178.44 USD
8/13/2025179.04 USD
8/12/2025178.68 USD
8/11/2025178.36 USD
8/8/2025176.97 USD
Access this data via the Eulerpool API
Get Free API Key

Quest Diagnostics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
9.25 B USD
1.26 B USD
854.00 M USD
Jan 1, 2024
9.87 B USD
1.35 B USD
871.00 M USD
Jan 1, 2025
11.04 B USD
1.60 B USD
992.00 M USD
Jan 1, 2026 (e)
11.96 B USD
1.97 B USD
1.25 B USD
Jan 1, 2027 (e)
12.51 B USD
2.06 B USD
1.35 B USD
Jan 1, 2028 (e)
13.04 B USD
2.15 B USD
1.46 B USD
Jan 1, 2029 (e)
13.71 B USD
2.26 B USD
1.62 B USD
Jan 1, 2030 (e)
11.56 B USD
1.90 B USD
1.67 B USD

Quest Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 6:19 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
7.497.527.717.537.739.4410.799.889.259.8711.0411.9612.5113.0413.7111.56
0.780.292.58-2.312.5922.1514.32-8.39-6.386.7011.788.374.614.245.12-15.70
37.8538.5838.7934.5934.8038.5039.0234.7433.0032.8631.9331.9331.9331.9331.9331.93
2.842.902.992.612.693.634.213.433.053.243.523.823.994.164.383.69
1.401.281.171.101.231.972.531.431.261.351.601.972.062.152.261.90
18.6716.9915.1114.5415.9320.8923.4714.4513.6413.6314.5316.4716.4716.4716.4716.47
0.710.650.770.740.861.432.000.950.850.870.991.251.351.461.621.67
27.52-9.0319.69-4.6616.5866.7839.41-52.58-9.731.9913.8926.017.848.5310.663.40
1.471.581.801.952.122.212.422.602.792.963.153.443.693.97––
13.957.4813.928.338.724.259.507.447.316.096.429.217.277.59––
144.00141.00139.00137.00136.00137.00125.00115.00113.00113.00112.00112.00112.00112.00112.00112.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Quest Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Quest Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Quest Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Quest Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Quest Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Quest Diagnostics stock margins

The Quest Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Quest Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Quest Diagnostics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
39.02 %
23.47 %
18.49 %
Jan 1, 2022
34.74 %
14.45 %
9.57 %
Jan 1, 2023
33.00 %
13.64 %
9.23 %
Jan 1, 2024
32.86 %
13.63 %
8.82 %
Jan 1, 2025
31.93 %
14.53 %
8.99 %
Jan 1, 2026 (e)
31.93 %
16.48 %
10.46 %
Jan 1, 2027 (e)
31.93 %
16.48 %
10.78 %
Jan 1, 2028 (e)
31.93 %
16.48 %
11.22 %

Quest Diagnostics Stock Revenue, EBIT, Earnings per Share

The Quest Diagnostics earnings per share therefore indicates how much revenue Quest Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
86.30 USD
20.26 USD
15.96 USD
Jan 1, 2022
85.94 USD
12.42 USD
8.23 USD
Jan 1, 2023
81.88 USD
11.17 USD
7.56 USD
Jan 1, 2024
87.36 USD
11.91 USD
7.71 USD
Jan 1, 2025
98.53 USD
14.31 USD
8.86 USD
Jan 1, 2026 (e)
105.83 USD
17.59 USD
11.07 USD
Jan 1, 2027 (e)
110.71 USD
18.40 USD
11.94 USD
Jan 1, 2028 (e)
115.40 USD
19.18 USD
12.95 USD

Quest Diagnostics business model & stock analysis

Quest Diagnostics Inc is a leading company in the field of diagnostic information and services, headquartered in New Jersey, USA. The company is dedicated to providing medical professionals and patients worldwide with fast, accurate, and preventive diagnostic tests. The history of Quest Diagnostics dates back to 1967 when the company MetPath was founded by Dr. Paul A. Brown. In the following years, several acquisitions and mergers took place, eventually leading to the establishment of Quest Diagnostics in 1996. Since then, the company has continuously evolved and now offers a wide range of diagnostic tests and services, ranging from the analysis of blood samples to genetic testing procedures. The business model of Quest Diagnostics is based on providing high-quality and individualized information to medical professionals and patients to assist in the diagnosis, treatment, and cure of their health problems. The company works closely with doctors, hospitals, and other medical institutions worldwide to offer a comprehensive range of innovative diagnostic products, procedures, and technologies tailored to meet specific needs. Quest Diagnostics offers a wide range of services, ranging from laboratory testing to data management and clinical trials. The company has various business segments, including the Diagnostic Services business, the Medical Research Services business, and the Information Services business. In the field of Diagnostic Services, Quest Diagnostics offers a broad spectrum of laboratory tests divided into different categories such as cancer diagnostics, cardiology, endocrinology, immunology, and infectious diseases. The company also provides a variety of genetic tests that enable precise analysis of individual genomes, supporting the diagnosis and treatment of various genetic disorders. In the medical research field, Quest Diagnostics provides a range of services to support clinical trials and drug development. The company also offers a wide range of laboratory tests used in biomedical research to improve people's health and well-being. The Information Services business segment of Quest Diagnostics mainly focuses on providing innovative solutions in the field of data management and information technology. This includes the development of software tools that can be used for the analysis and management of health data. Additionally, the company offers consulting services to help medical professionals address challenges related to information processing and data integration. Quest Diagnostics is a company based on innovation and knowledge that collaborates closely with doctors, clinics, and other medical facilities worldwide to offer a relatively comprehensive range of need-specific diagnostic products, procedures, and solutions. From cancer diagnostics to genomic diagnostics, from clinical trials to information and data services, and a wide range of molecular diagnostic tests and laboratory analyses, Quest Diagnostics provides top-notch solutions for optimal patient care, contributing to the goal of improving global healthcare for people worldwide.

Quest Diagnostics SWOT Analysis

Strengths

Quest Diagnostics Inc is a leading provider of diagnostic testing, information, and services, with a strong market presence and brand reputation.

The company has a vast network of laboratories and patient service centers, enabling it to serve a wide range of customers across the United States.

Quest Diagnostics Inc has developed advanced testing technologies and capabilities, allowing for accurate and reliable test results.

Weaknesses

Quest Diagnostics Inc faces intense competition in the diagnostic testing industry, which could impact its market share and pricing power.

The company relies on third-party payers, such as insurance companies, for a significant portion of its revenue, making it vulnerable to changes in reimbursement policies.

Quest Diagnostics Inc's operations are subject to various regulations and compliance requirements, which could increase costs and limit flexibility.

Opportunities

The increasing demand for personalized medicine and genetic testing presents growth opportunities for Quest Diagnostics Inc.

Expanding into emerging markets, such as Asia and Latin America, could help Quest Diagnostics Inc tap into new customer bases and drive revenue growth.

Technology advancements, such as the integration of artificial intelligence in diagnostics, offer opportunities for Quest Diagnostics Inc to enhance its testing capabilities and improve efficiency.

Threats

Changes in healthcare policies and regulations can pose significant challenges to Quest Diagnostics Inc's operations and profitability.

Increasing pricing pressure from payers and the growing trend of cost containment in healthcare could negatively impact Quest Diagnostics Inc's financial performance.

Competitors in the industry continuously strive to develop innovative diagnostic solutions, posing a threat to Quest Diagnostics Inc's market position.

Quest Diagnostics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Quest Diagnostics Employees
Details
Date
Quest Diagnostics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Quest Diagnostics Segments

Quest Diagnostics Revenue by Segment (1/4)

  • 3 Years

  • 5 Years

  • Max

Routine clinical testing and other services
Routine clinical testing services
Gene-based and esoteric (including advanced diagnostics) testing services
COVID-19 testing services
Anatomic pathology testing services
All other services
Details
Date
Routine clinical testing and other services
Routine clinical testing services
Gene-based and esoteric (including advanced diagnostics) testing services
COVID-19 testing services
Anatomic pathology testing services
All other services
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
3.84 B USD
2.10 B USD
2.72 B USD
482.00 M USD
298.00 M USD
Jan 1, 2021
4.29 B USD
0.00 USD
2.88 B USD
2.77 B USD
553.00 M USD
294.00 M USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Quest Diagnostics Revenue by Segment (2/4)

  • 3 Years

  • 5 Years

  • Max

Routine clinical testing services
Gene-based and esoteric (including advanced diagnostics) testing services
Anatomic pathology testing services
All other services
Details
Date
Routine clinical testing services
Gene-based and esoteric (including advanced diagnostics) testing services
Anatomic pathology testing services
All other services
Jan 1, 2018
4.22 B USD
2.41 B USD
578.00 M USD
327.00 M USD
Jan 1, 2019
4.21 B USD
2.62 B USD
579.00 M USD
321.00 M USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Quest Diagnostics Revenue by Segment (3/4)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

DIS business
All other operating segments
DS businesses
Details
Date
DIS business
Clinical laboratory testing business
All other operating segments
DS businesses
Jan 1, 2018
7.20 B USD
0.00 USD
327.00 M USD
0.00 USD
Jan 1, 2019
7.41 B USD
0.00 USD
321.00 M USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
298.00 M USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
294.00 M USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
274.00 M USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
276.00 M USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
258.00 M USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
250.00 M USD

Quest Diagnostics Revenue by Segment (4/4)

  • 3 Years

  • 5 Years

  • Max

DIS business
Details
Date
DIS business
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
9.14 B USD
Jan 1, 2021
10.49 B USD
Jan 1, 2022
9.61 B USD
Jan 1, 2023
8.98 B USD
Jan 1, 2024
9.61 B USD
Jan 1, 2025
10.79 B USD

Quest Diagnostics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Quest Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

Quest Diagnostics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Quest Diagnostics shares outstanding

The number of shares of Quest Diagnostics was 112 M in 2025. This indicates how many shares Quest Diagnostics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
125.00 M Stocks
Jan 1, 2022
115.00 M Stocks
Jan 1, 2023
113.00 M Stocks
Jan 1, 2024
113.00 M Stocks
Jan 1, 2025
112.00 M Stocks
Jan 1, 2026 (e)
112.00 M Stocks
Jan 1, 2027 (e)
112.00 M Stocks
Jan 1, 2028 (e)
112.00 M Stocks

Quest Diagnostics stock splits

In Quest Diagnostics's history, there have been no stock splits.

Quest Diagnostics Dividend History

23 years of dividend payments · 11 consecutive increases

YearAnnual DividendYoY ChangePayments
20261.66USDYTD—2×
Jan 13, 20260.80USD 0.0%1/2
Apr 6, 20260.86USD↑ 7.5%2/2
20253.15USD↑ 6.4%4×
Jan 14, 20250.75USD 0.0%1/4
Apr 7, 20250.80USD↑ 6.7%2/4
Jul 7, 20250.80USD 0.0%3/4
Oct 3, 20250.80USD 0.0%4/4
20242.96USD↑ 6.1%4×
20232.79USD↑ 7.3%4×
20222.60USD↑ 7.4%4×
20212.42USD↑ 9.5%4×
20202.21USD↑ 4.2%4×
20192.12USD↑ 8.7%4×
20181.95USD↑ 8.3%4×
20171.80USD↑ 13.9%4×

Quest Diagnostics dividend history and estimates

In 2025, Quest Diagnostics paid a dividend amounting to 3.15 USD. Dividend means that Quest Diagnostics distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
2.42 USD
0.00 USD
Jan 1, 2022
2.60 USD
0.00 USD
Jan 1, 2023
2.79 USD
0.00 USD
Jan 1, 2024
2.96 USD
0.00 USD
Jan 1, 2025
3.15 USD
0.00 USD
Jan 1, 2026 (e)
0.86 USD
2.58 USD
Jan 1, 2027 (e)
0.00 USD
3.69 USD
Jan 1, 2028 (e)
0.00 USD
3.97 USD

Quest Diagnostics dividend payout ratio

In 2025, Quest Diagnostics had a payout ratio of 35.56%. The payout ratio indicates the percentage of the company's profits that Quest Diagnostics distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
15.16 %
Jan 1, 2022
31.61 %
Jan 1, 2023
36.92 %
Jan 1, 2024
38.40 %
Jan 1, 2025
35.56 %
Jan 1, 2026 (e)
31.08 %
Jan 1, 2027 (e)
30.95 %
Jan 1, 2028 (e)
30.64 %

Current Quest Diagnostics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.50 %
Buy
54.17 % (13)
Hold
45.83 % (11)
Sell
0.00 % (0)
12M Price Target
207.06
Last Price
238.50
Currency
USD
12M Return Potential
-13.18 %
LTM Return
0 %

Quest Diagnostics Analyst Rating Actions

DateFirmActionRatingReliability
7/28/2026
JP Morgan
JP Morgan
MaintainedNeutral80
7/24/2026
UBS
UBS
MaintainedNeutral51
7/24/2026
Truist Securities
Truist Securities
MaintainedHold–
7/24/2026
Mizuho
Mizuho
MaintainedOutperform31
7/24/2026
Barclays
Barclays
MaintainedOverweight33
7/24/2026
Baird
Baird
MaintainedNeutral–
7/13/2026
Baird
Baird
MaintainedNeutral–
4/22/2026
UBS
UBS
MaintainedNeutral51
4/22/2026
Truist Securities
Truist Securities
MaintainedHold–
4/22/2026
Barclays
Barclays
MaintainedOverweight33

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Quest Diagnostics Earnings Calls

2025

Quest Diagnostics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/23/20262.86USD-3.00 BUSD-2026 Q2
4/21/20262.37USD-2.85 BUSD-2026 Q1
2/10/20262.38USD-2.78 BUSD-2025 Q4
4/25/20242.11USD-2.34 BUSD-2024 Q1
1/31/20242.16USD-2.28 BUSD-2023 Q4
7/19/20232.22USD-2.31 BUSD-2023 Q2
4/19/20232.09USD-2.22 BUSD-2023 Q1
2/1/20231.92USD-2.28 BUSD-2022 Q4
10/20/20222.22USD-2.38 BUSD-2022 Q3
7/21/20222.32USD-2.38 BUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Quest Diagnostics stock

82/100
99
Environment
99
Social
48
Governance
E

Environment

20
Scope 1 - Direct Emissions113,925
Scope 2 - Indirect emissions from purchased energy83,631
Scope 3 - Indirect emissions within the value chain631,003
Total CO₂ emissions197,556
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees72.511
Percentage of women in management—
Percentage of Asian employees13.7
Share of Asian management12
Percentage of Hispanic/Latino employees17.2
Hispano/Latino Management share9.4
Percentage of Black employees23.7
Black Management Share12.6
Percentage of white employees42.3
White Management Share63.1
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Quest Diagnostics shareholder structure

% Name
8.11707%
BLACKROCK, INC.
BLACKROCK, INC.
6.32360%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
5.57344%
PRICE T ROWE ASSOCIATES INC /MD/
PRICE T ROWE ASSOCIATES INC /MD/
5.38177%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.76179%
STATE STREET CORP
STATE STREET CORP
3.55065%
BOSTON PARTNERS
BOSTON PARTNERS
...

Quest Diagnostics Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
100.00%
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated
SEC ↗
41.21%
Bayou Well Holdings Company, LLC
Bayou Well Holdings Company, LLC
SEC ↗
22.10%
Reporting Persons.
Reporting Persons.
SEC ↗
12.91%
04-2507163)
04-2507163)
SEC ↗
10.91%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
10.70%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
8.40%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
7.53%
Vanguard Capital Management
Vanguard Capital Management
SEC ↗
7.30%
W. FIFIELD WHITMAN III
W. FIFIELD WHITMAN III
SEC ↗
7.00%
The Column Group, LP
The Column Group, LP
SEC ↗

Quest Diagnostics Executives and Management Board

18 members · avg. age 63 · 28 % women

JD

Mr. James Davis (62)

Chairman of the Board, President, Chief Executive Officer · since 2013

14.40 M USD

Management

SS

Mr. Sam Samad (55)

Chief Financial Officer, Executive Vice President

4.07 M USD
CD

Ms. Catherine Doherty (62)

Executive Vice President - Regional Businesses

3.29 M USD
MP

Mr. Michael Prevoznik (63)

Senior Vice President, General Counsel

2.43 M USD
KK

Mr. Karthik Kuppusamy (55)

Senior Vice President - Clinical Solutions

2.28 M USD
PP

Mr. Patrick Plewman (58)

Senior Vice President - Diagnostic Services

1.98 M USD
AB

Ms. Adrienne Brott

Senior Vice President, Chief Quality and Regulatory Affairs Officer

–

Board of Directors

TR

Mr. Timothy Ring (67)

Lead Independent Director

377,966.00 USD
GP

Mr. Gary Pfeiffer (75)

Independent Director

360,716.00 USD
VG

Ms. Vicky Gregg (70)

Independent Director

344,716.00 USD
DM

Ms. Denise Morrison (71)

Independent Director

344,716.00 USD
TM

Mr. Timothy Main (67)

Independent Director

342,716.00 USD
TD

Ms. Tracey Doi (64)

Independent Director

327,716.00 USD

Quest Diagnostics Supply Chain

Quest Diagnostics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Nameβ 1YTrend
1
Siemens Healthineers AG
Supplier
0.64
0.82
0.47
0.80
0.79
0.89
—
2
IQVIA Holdings
Supplier·Customer·Life Sciences Tools & Services·US
-0.43
-0.36
0.06
0.75
0.69
0.85
1.18
3
ePlus inc.
Supplier·Electronic Equipment, Instruments & Components·US
0.20
0.15
0.04
0.24
0.39
0.72
0.55
4
UnitedHealth Group
Customer·Health Care Providers & Services·US
0.17
-0.26
0.07
-0.06
-0.01
0.72
-0.01
5
OptimizeRx Corporation
Supplier·Health Care Technology·US
0.75
0.05
0.27
0.74
0.40
0.65
—
#Nameβ 1YTrend
1
Oxford Immunotec Global Plc
Supplier·GB
0.82
0.52
-0.37
-0.50
—
—
—
2
Ortho Cli Dgnst Rg
Supplier·Health Care Equipment & Supplies·US
0.68
0.51
0.34
0.77
0.22
—
—
3
Ginkgo Bioworks A
Supplier·Customer·Chemicals·US
0.52
-0.10
-0.03
0.83
0.43
—
—
4
Castlight Health, Inc.
Supplier·Customer·Health Care Technology·US
-0.01
0.32
-0.37
-0.19
0.05
—
—
5
Quanterix Corporation
Supplier·Life Sciences Tools & Services·US
-0.08
-0.31
0.07
0.72
0.17
—
—

Frequently asked questions about Quest Diagnostics

Quest Diagnostics Inc. operates as a provider of diagnostic testing and information services. It offers a range of services including routine testing, complex and specialized testing, and diagnostic information services. The company operates a network of laboratories, patient service centers, and other testing sites across the United States. Quest Diagnostics Inc. collaborates with physicians, hospitals, and other healthcare organizations to help improve patient care. Its business model revolves around delivering accurate and reliable diagnostic testing results in a timely manner, assisting healthcare providers in making informed decisions, and ultimately improving patient outcomes.

Quest Diagnostics Inc is primarily active in the healthcare industry.

The main competitors of Quest Diagnostics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Sonic Healthcare Limited, and Bio-Reference Laboratories.

Quest Diagnostics Inc is a leading provider of diagnostic information services. It was founded in 1967 as MetPath and became Quest Diagnostics in 1997. The company offers a wide range of services, including lab testing, clinical trials, and healthcare IT solutions. With a strong focus on innovation and quality, Quest Diagnostics has become a trusted name in the healthcare industry. It operates a vast network of laboratories across the United States, serving millions of patients and healthcare professionals. Quest Diagnostics is known for its commitment to accuracy, efficiency, and delivering timely results, making it a reliable partner for both patients and healthcare providers.

Quest Diagnostics Inc has achieved several significant milestones throughout its history. One of its noteworthy achievements includes the development of innovative diagnostic tests and services that have revolutionized the healthcare industry. Additionally, Quest Diagnostics Inc has successfully established a vast network of laboratories and patient service centers, ensuring convenient access to high-quality diagnostic information services for patients worldwide. Furthermore, the company has received numerous accolades for its commitment to quality, including ISO 9001 certification for its laboratory operations. These accomplishments highlight Quest Diagnostics Inc as a leading provider of diagnostic information services and showcase its dedication to improving patient care and outcomes.

Quest Diagnostics Inc is primarily present in the United States.

Quest Diagnostics Inc represents values of empowerment, collaboration, and integrity. As a leading provider of diagnostic testing and information services, the company is committed to delivering high-quality healthcare solutions. Quest Diagnostics believes in patient-centric care and strives to improve both individual and public health outcomes. With a corporate philosophy focused on innovation and excellence, Quest Diagnostics prioritizes accuracy, efficiency, and accessibility in their diagnostic services. Through extensive research and development, the company continually advances medical technologies to contribute to the progress of the healthcare industry.

Analysts currently set an average price target of 202.57 USD for the Quest Diagnostics stock (median: 207.06 USD), implying -15.1 % versus the latest price. The consensus is based on 24 analyst ratings.

Quest Diagnostics Analyst Price Targets 2026

24 analysts currently rate the Quest Diagnostics stock: 13 recommend buying, 11 holding and 0 selling. For 2026, analysts expect Quest Diagnostics to generate revenue of 11.96 B USD and earnings per share of 11.17 USD.

Quest Diagnostics Analyst Price Targets 2026

Converted at the current exchange rate, the Quest Diagnostics share trades at 206.46 EUR (238.50 USD).

The Quest Diagnostics share (DGX) is listed on 8 stock exchanges, including: NYSE (DGX), XETRA (QDI.DE), Frankfurt (QDI.F), München (QDI.MU), Düsseldorf (QDI.DU), London (0KSX.L), London (0KSX.L), SIX (Zürich) (QDI.SW).

Quest Diagnostics Inc is a leading provider of diagnostic laboratory tests and services worldwide. The company serves medical laboratories, hospitals, clinics, physicians, as well as companies and insurers globally. The company's business strategy is based on providing high-quality laboratory facilities, state-of-the-art technology, and a high-quality laboratory workflow management platform. It operates over 2,200 patient centers in the United States and also offers a mobile laboratory service. The company is divided into three main segments: 1. Diagnostic information services, 2. Diagnostic services, and 3. Diagnostic solutions. Quest Diagnostics offers a wide range of products and services used to diagnose and treat diseases and conditions, including blood tests, hormone analyses, microbiology tests, genetic tests, immunology tests, and more. The company also operates a pathology laboratory that provides specialized services for cancer diagnosis and other critical diseases. It has also specialized in the development of tests for detecting COVID-19. Overall, Quest Diagnostics has a strong business model based on its leading position in the diagnostic market, a wide range of products and services, and a strong presence in the United States and growing international presence. The company is also focused on expanding its capabilities in digital health technology to meet the changing healthcare landscape.

The expected revenue of Quest Diagnostics is 11.96 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Quest Diagnostics is 1.25 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Quest Diagnostics is currently 21.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Quest Diagnostics stock.

The price-to-sales ratio (P/S) of Quest Diagnostics is currently 2.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Quest Diagnostics stock.

The Eulerpool Quality Score for Quest Diagnostics is 2/10.

The ISIN of Quest Diagnostics is US74834L1008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Quest Diagnostics is 904533. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Quest Diagnostics is DGX. The ticker symbol is used to trade Quest Diagnostics shares on the stock exchange.

Over the past 12 months, Quest Diagnostics paid a dividend of 3.15 USD . This corresponds to a dividend yield of about 1.32 %. For the coming 12 months, Quest Diagnostics is expected to pay a dividend of 3.69 USD.

The current dividend yield of Quest Diagnostics is 1.32 %.

Quest Diagnostics pays a dividend, distributed in the months of , , , .

Quest Diagnostics paid dividends every year for the past 22 years.

For the upcoming 12 months, dividends amounting to 3.69 USD are expected. This corresponds to a dividend yield of 1.55 %.

Quest Diagnostics is assigned to the 'Health' sector.

To receive the latest dividend of Quest Diagnostics from amounting to 0.86 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Quest Diagnostics distributed 3 USD as dividends.

The dividends of Quest Diagnostics are distributed in USD.

All fundamentals and in-depth analysis of Quest Diagnostics

Our stock analysis for Quest Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quest Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Quest Diagnostics Stock
Quest Diagnostics Revenue→
Quest Diagnostics Stock
Quest Diagnostics Net Income→
Quest Diagnostics Stock
Quest Diagnostics P/E→
Quest Diagnostics Stock
Quest Diagnostics P/S→
Quest Diagnostics Stock
Quest Diagnostics EBIT→
Quest Diagnostics Stock
Quest Diagnostics Dividend→
Quest Diagnostics Stock
Quest Diagnostics Directors Dealings→
Quest Diagnostics Stock
Quest Diagnostics Stocks→
Quest Diagnostics Stock
Quest Diagnostics Market capitalization→
Quest Diagnostics Stock
Quest Diagnostics Debt→
Quest Diagnostics Stock
Quest Diagnostics Liabilities→
Quest Diagnostics Stock
Quest Diagnostics Equity→
Quest Diagnostics Stock
Quest Diagnostics AAQS→
Quest Diagnostics Stock
Quest Diagnostics Employees→
Quest Diagnostics Stock
Quest Diagnostics ROE→
Quest Diagnostics Stock
Quest Diagnostics ROA→
Quest Diagnostics Stock
Quest Diagnostics ROCE→
Quest Diagnostics Stock
Quest Diagnostics News→
Quest Diagnostics Stock
Quest Diagnostics Analyst Price Targets→

Health Stocks

Quest LaboratoriesQuantum-SiQuest PharmatechQuantum Medical TransportQuick-Med TechnologiesQuantum HealthcareQuidelQuantum GenomicsQuince TherapeuticsQuanterixQuoin Pharmaceuticals Ltd DRCQuantaMatrixAll Stocks A–Z →